BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brent MB, Thomsen JS, Brüel A. Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice. Sci Rep 2021;11:12258. [PMID: 34112892 DOI: 10.1038/s41598-021-91729-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Ullal J, Kutney K, Williams KM, Weber DR. Treatment of cystic fibrosis related bone disease. Journal of Clinical & Translational Endocrinology 2022;27:100291. [DOI: 10.1016/j.jcte.2021.100291] [Reference Citation Analysis]
2 Brent MB, Simonsen U, Thomsen JS, Brüel A. Effect of Acetazolamide and Zoledronate on Simulated High Altitude-Induced Bone Loss. Front Endocrinol 2022;13:831369. [DOI: 10.3389/fendo.2022.831369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Krüger BT, Steppe L, Vettorazzi S, Haffner-luntzer M, Lee S, Dorn A, Ignatius A, Tuckermann J, Ahmad M. Inhibition of Cdk5 Ameliorates Skeletal Bone Loss in Glucocorticoid-Treated Mice. Biomedicines 2022;10:404. [DOI: 10.3390/biomedicines10020404] [Reference Citation Analysis]
4 Brent MB, Brüel A, Thomsen JS. Sparse dose-dependent difference in skeletal effects of short-term glucocorticoid excess in outbred Swiss mice. Endocrine and Metabolic Science 2021;5:100114. [DOI: 10.1016/j.endmts.2021.100114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Brent MB. Abaloparatide: A review of preclinical and clinical studies. Eur J Pharmacol 2021;909:174409. [PMID: 34364879 DOI: 10.1016/j.ejphar.2021.174409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]